當(dāng)前位置：   首頁 > 需求大廳

 >  特色服務(wù) 

目的：將表中的藥品名稱寫法規(guī)范化。 標(biāo)準(zhǔn)：藥智網(wǎng)國產(chǎn)藥品數(shù)據(jù)庫和藥品數(shù)據(jù)庫的寫法作為規(guī)范寫法。 方法： 用名稱字段內(nèi)容（不規(guī)范的寫法可截取名稱的部分進(jìn)行搜索），到藥智網(wǎng)國產(chǎn)藥品數(shù)據(jù)庫或藥品數(shù)據(jù)庫進(jìn)行查找（企業(yè)是國內(nèi)的就在國產(chǎn)藥品數(shù)據(jù)庫找，國外的就在藥品數(shù)據(jù)庫找），找到對(duì)應(yīng)企業(yè)的藥品名稱寫法，填寫到規(guī)范名稱字段中去。   [更多]

標(biāo)題：重金求購Gluconolactone《 USP41-NF36 》的藥典標(biāo)準(zhǔn)一份. 詳細(xì)要求： 需求名稱：Gluconolactone《 USP41-NF36 》的藥典標(biāo)準(zhǔn) 具體要求：《 USP41-NF36 》 要求時(shí)間：請(qǐng)?jiān)?017年12月29日之前 交稿方式：直接點(diǎn)擊交稿在線交稿就是了，我會(huì)每天過來看的，謝謝各位藥智的戰(zhàn)友們   [更多]

Codeine Phosphate Tablets”《 BP2017 》的藥典標(biāo)準(zhǔn)一份.   [更多]

標(biāo)題：求購克拉霉素緩釋片USP41標(biāo)準(zhǔn) 詳細(xì)要求： 需求名稱：克拉霉素緩釋片標(biāo)準(zhǔn) 具體要求：USP42 要求時(shí)間：請(qǐng)?jiān)?019年05月15日之前 交稿方式：直接點(diǎn)擊交稿在線交稿就是了，我會(huì)每天過來看的，謝謝各位藥智的戰(zhàn)友們   [更多]

求購Rotigotine 《EP9.6》的藥典標(biāo)準(zhǔn)一份   [更多]

文獻(xiàn)標(biāo)題： 1："kidney Int. 2015 Jul;88(1):17-27. doi: 10.1038/ki.2015.59. Epub 2015 Mar 18. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Chapman AB1, Devuyst O2, Eckardt KU3, Gansevoort RT4, Harris T5, Horie S6, Kasiske BL7, Odland D8, Pei Y9, Perrone RD10, Pirson Y11, Schrier RW12, Torra R13, Torres VE14, Watnick T15, Wheeler DC16; Conference Participants." 2："Kidney Int. 2015 Oct;88(4):676-83. doi: 10.1038/ki.2015.28. Epub 2015 Mar 4. Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management--A KDIGO consensus report. Eckardt KU1, Alper SL2, Antignac C3,4, Bleyer AJ5, Chauveau D6, Dahan K7, Deltas C8, Hosking A9, Kmoch S10, Rampoldi L11, Wiesener M1, Wolf MT12, Devuyst O13; Kidney Disease: Improving Global Outcomes." 3：alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 1 trials.the lan lancet et oncology. 4：Topical treatment of glaucoma: established and emerging pharmacology 5：Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.   [更多]

求購Rotigotine Transdermal System《USP43-NF38》的藥典標(biāo)準(zhǔn)一份   [更多]

求購Monographs: Medicinal and Pharmaceutical Substances:Rotigotine《BP2020》的藥典標(biāo)準(zhǔn)一份   [更多]

求購“Oseltamivir phosphate”《 EP9.2 》的藥典標(biāo)準(zhǔn)一份.   [更多]

1.Nihon Yakurigaku Zasshi. 2013 Jul;142(1):39-46. doi: 10.1254/fpj.142.39. Pharmacological and clinical properties of AIMIX combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate. 2.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 3.Clin Ther. 2012 Aug;34(8):1705-19. doi: 10.1016/j.clinthera.2012.06.026. Epub 2012 Jul 30. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 4.Clin Ther. 2012 Aug;34(8):1720-34.e3. doi: 10.1016/j.clinthera.2012.07.001. Epub 2012 Jul 30. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 5.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 6J Cardiol. 2019 Mar 20. pii: S0914-5087(19)30053-X. doi: 10.1016/j.jjcc.2019.03.001. [Epub ahead of print] Arginine vasopressin antagonism in heart failure: Current status and possible new directions. Goldsmith SR1. 7.Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability 8.Expert Rev Neurother. 2017 Jan;17(1):59-75. Epub 2016 Oct 20. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology. Tramutola A1, Arena A1,   [更多]